Cargando…

Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy

Hereditary amyloidosis associated with mutations in the transthyretin gene (hATTR) is a progressive devastating disease, with a fatal outcome occurring within 10years after onset. In recent years, TTR gene silencing therapy appeared as a promising therapeutic strategy, showing evidence that disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gentile, Luca, Russo, Massimo, Luigetti, Marco, Bisogni, Giulia, Di Paolantonio, Andrea, Romano, Angela, Guglielmino, Valeria, Arimatea, Ilenia, Sabatelli, Mario, Toscano, Antonio, Vita, Giuseppe, Mazzeo, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073153/ https://www.ncbi.nlm.nih.gov/pubmed/33921571 http://dx.doi.org/10.3390/brainsci11040515

Ejemplares similares

Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care
por: Luigetti, Marco, et al.
Publicado: (2020)

hATTR Pathology: Nerve Biopsy Results from Italian Referral Centers
por: Luigetti, Marco, et al.
Publicado: (2020)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

A retrospective survey of patients with hereditary transthyretin-mediated (hATTR) amyloidosis treated with patisiran in real-world clinical practice in Belgium
por: De Bleecker, Jan L., et al.
Publicado: (2023)

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2020)

Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines
por: Benson, M D, et al.
Publicado: (2020)

Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy
por: Gendre, Thierry, et al.
Publicado: (2019)

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
por: Judge, Daniel P., et al.
Publicado: (2020)

Renal Involvement in Hereditary Transthyretin Amyloidosis: An Italian Single-Centre Experience
por: Ferraro, Pietro Manuel, et al.
Publicado: (2021)

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2017)

Nerve Conduction Studies of Dorsal Sural Nerve: Normative Data and Its Potential Application in ATTRv Pre-Symptomatic Subjects
por: Luigetti, Marco, et al.
Publicado: (2022)

Modified Technique of Ex-PRESS(®) Filtration Device Combined with a Scleral Pocket for Hereditary Transthyretin Amyloidosis (hATTR) Secondary Open-Angle Glaucoma
por: Vieira, Rita, et al.
Publicado: (2023)

Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran
por: Di Stefano, Vincenzo, et al.
Publicado: (2022)

Estimating the fiscal impact of rare diseases using a public economic framework: a case study applied to hereditary transthyretin-mediated (hATTR) amyloidosis
por: Connolly, Mark P., et al.
Publicado: (2019)

Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
por: Gentile, Luca, et al.
Publicado: (2021)

A compound score to screen patients with hereditary transthyretin amyloidosis
por: Tozza, Stefano, et al.
Publicado: (2022)

Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation
por: Schmidt, Hartmut H., et al.
Publicado: (2022)

Quality of life in ATTR amyloidosis
por: Lane, Thirusha, et al.
Publicado: (2015)

Pathological Findings in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Single-Center Experience
por: Luigetti, Marco, et al.
Publicado: (2020)

Muscle MRI as a Useful Biomarker in Hereditary Transthyretin Amyloidosis: A Pilot Study
por: Primiano, Guido, et al.
Publicado: (2021)

Phenotypic Differences of Glu89Gln Genotype in ATTR Amyloidosis From Endemic Loci: Update From THAOS
por: Gentile, Luca, et al.
Publicado: (2021)

Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years
por: Gentile, L., et al.
Publicado: (2020)

Guidelines for genetic counselling in ATTR amyloidosis
por: Sequeiros, Jorge
Publicado: (2015)

Heart transplantation in hereditary ATTR amyloidosis
por: Slama, M
Publicado: (2015)

Diagnosis and Treatment of AL and ATTR Amyloidosis
por: Faiman, Beth, et al.
Publicado: (2021)

Small Fibre Involvement in Multifocal Motor Neuropathy Explored with Sudoscan: A Single-Centre Experience
por: Luigetti, Marco, et al.
Publicado: (2020)

Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects
por: Russo, Massimo, et al.
Publicado: (2020)

A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2020)

Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
por: Dixon, Stacy, et al.
Publicado: (2023)

Correction to: A Review of Patisiran (ONPATTRO®) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis
por: Urits, Ivan, et al.
Publicado: (2021)

Real‐life experience with inotersen in hereditary transthyretin amyloidosis with late‐onset phenotype: Data from an early‐access program in Italy
por: Luigetti, Marco, et al.
Publicado: (2022)

ATTR Amyloidosis: development of cardiac symptoms during 6 years of follow up in different ATTR-variants
por: Klaassen, Sebastiaan, et al.
Publicado: (2015)

Glavonoid, a possible supplement for prevention of ATTR amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2021)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Conventional heart failure therapy in cardiac ATTR amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023)

Cardiac amyloidosis: diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR)
por: Rahman, Tanvir, et al.
Publicado: (2021)

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)
por: Gonzalez-Duarte, Alejandra, et al.
Publicado: (2021)

Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin‐Mediated Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Reassessing IVIg therapy in chronic inflammatory demyelinating polyradiculoneuropathy during COVID-19: a chance to verify the need for chronic maintenance therapy
por: Romozzi, Marina, et al.
Publicado: (2021)

A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
por: González-Moreno, Juan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dnk2aj2g3mgr235ejteg4pqj8q